PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (SerendipityPB1)

Overview
The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or frequent urination related to inherited nephrogenic diabetes insipidus as an inherited condition or as an acquired condition from prior treatment with lithium.

Eligibility Criteria

• Ages 18 years and older
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) diagnosis
• Participating in the tolvaptan arm
• Estimated GFR ≥ 30 ml/min
• Diagnosis of nephrogenic diabetes insipidus (NDI) (congenital, tolvaptan-induced, or lithium-induced).

Additional inclusion/exclusion criteria may apply

Locations

Florida

• Mayo Clinic
• Jacksonville, FL 32224
• Contact: Clinical Studies Unit 904-953-4254 King.Cameron@mayo.edu
• Contact: Trinity Hooks 904-953-3057 Hooks.Trinity@mayo.edu

Principal Investigator: Fouad Chebib, MD